Literature DB >> 30233848

Does age over 80 years have to be a contraindication for lung cancer surgery-a nationwide database study.

Pierre-Benoit Pagès1,2, Anne-Sophie Mariet3, Arnaud Pforr1, Jonathan Cottenet3, Leslie Madelaine1, Halim Abou-Hanna1, Alain Bernard1, Catherine Quantin3,4,5.   

Abstract

BACKGROUND: Nowadays surgery remains the best treatment for localized lung cancer (LC). However, patients over 80 years old are often denied surgery because of the postoperative risk of death. This study aimed to estimate in-hospital mortality (IHM) and determine whether age over 80 is the most important predictor of IHM after LC surgery.
METHODS: From January 2005 to December 2015, 97,440 patients, including 4,438 patients over 80 years old, were operated on for LC and recorded in the French Administrative Database. Characteristics of patients, hospitals and surgery were analysed.
RESULTS: Crude IHM was 3.73% (n=3,639) and 7.77% (n=345) for the over 80s vs. 3.54% (n=3,294) for younger patients (P<0.0001). In multivariate analysis, predictive factors for IHM with the odds ratios (OR) were: 2.60 for age ≥80 (95% CI: 2.30-2.94; P=0.0001), 5.85 for a previous liver disease (95% CI: 4.79-7.16; P=0.0001) and 5 for previous lung disease (95% CI: 4.25-5.9; P=0.0001). IHM was also linked to hospital volume with an OR of 0.75 (95% CI: 0.69-0.81; P=0.0001) and a linear decrease for predicted IHM according to hospital volume for the over 80s. Adjusted ORs were 1.15 (95% CI: 0.96-1.4; P=0.0116) for lobectomy, 2.18 for bilobectomy (95% CI: 1.7-2.8; P=0.0001) and 3.83 (95% CI: 3.2-4.6; P=0.0001) for pneumonectomy.
CONCLUSIONS: Concerning IHM, age ≥80 had a lower weight than did a previous pulmonary or liver disease and the type of pulmonary resection. Patients over 80s with localized LC and no significant comorbidities should be referred for surgery if lobectomy or sublobar resection could be performed.

Entities:  

Keywords:  Over 80s; in-hospital mortality (IHM); lobectomy; nationwide database; predictive factors

Year:  2018        PMID: 30233848      PMCID: PMC6129874          DOI: 10.21037/jtd.2018.07.12

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  25 in total

1.  Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition.

Authors:  Shigeki Sawada; Eisaku Komori; Naoyuki Nogami; Akihiro Bessho; Yoshihiko Segawa; Tetsu Shinkai; Masao Nakata; Motohiro Yamashita
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

2.  ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy).

Authors:  A Brunelli; A Charloux; C T Bolliger; G Rocco; J-P Sculier; G Varela; M Licker; M K Ferguson; C Faivre-Finn; R M Huber; E M Clini; T Win; D De Ruysscher; L Goldman
Journal:  Eur Respir J       Date:  2009-07       Impact factor: 16.671

3.  Impact of lobectomy for non-small-cell lung cancer on respiratory function in octogenarian patients with mild to moderate chronic obstructive pulmonary disease.

Authors:  Cristian Rapicetta; Sara Tenconi; Luca Voltolini; Luca Luzzi; Valerio Scala; Giuseppe Gotti
Journal:  Eur J Cardiothorac Surg       Date:  2010-09-15       Impact factor: 4.191

Review 4.  Impact of hepatic cirrhosis on outcome in adult cardiac surgery.

Authors:  Ioannis Dimarakis; Stuart Grant; Rebecca Corless; Theodore Velissaris; Martin Prince; Ben Bridgewater; George Asimakopoulos
Journal:  Thorac Cardiovasc Surg       Date:  2014-10-07       Impact factor: 1.827

5.  Risk model of in-hospital mortality after pulmonary resection for cancer: a national database of the French Society of Thoracic and Cardiovascular Surgery (Epithor).

Authors:  Alain Bernard; Caroline Rivera; Pierre Benoit Pages; Pierre Emmanuel Falcoz; Eric Vicaut; Marcel Dahan
Journal:  J Thorac Cardiovasc Surg       Date:  2010-08-09       Impact factor: 5.209

6.  Risk factor for respiratory death after lung cancer surgery in octogenarians.

Authors:  Katsunari Matsuoka; Mitsuhiro Ueda; Yoshihiro Miyamoto
Journal:  Asian Cardiovasc Thorac Ann       Date:  2015-09-18

7.  Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators.

Authors:  K M Taylor; M L Feldstein; R T Skeel; K J Pandya; P Ng; P P Carbone
Journal:  J Clin Oncol       Date:  1994-09       Impact factor: 44.544

8.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

9.  Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  John A Howington; Matthew G Blum; Andrew C Chang; Alex A Balekian; Sudish C Murthy
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Alessandro Brunelli; Anthony W Kim; Kenneth I Berger; Doreen J Addrizzo-Harris
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

View more
  1 in total

1.  Interest of anatomical segmentectomy over lobectomy for lung cancer: a nationwide study.

Authors:  Elodie Berg; Leslie Madelaine; Jean-Marc Baste; Marcel Dahan; Pascal Thomas; Pierre-Emmanuel Falcoz; Emmanuel Martinod; Alain Bernard; Pierre-Benoit Pagès
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.